Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03705260
Other study ID # HUM00147295
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 26, 2018
Est. completion date January 20, 2021

Study information

Verified date February 2021
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the Twine / University of Michigan Diabetes Quality Improvement Initiative is to improve diabetes care quality using real time feedback with continuous glucose monitoring (CGM) and dietary coaching for lower carbohydrate consumption in a high-risk sub-cohort of outpatients with type 2 diabetes (T2D).


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date January 20, 2021
Est. primary completion date February 7, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Michigan Medicine patient treated by a physician in the Family Medicine Department at the Chelsea Health Center - Diagnosis of T2D as recorded in the patient's problem list or as documented by medication list and lab results - HbA1C >8 for the high-risk sub-cohort Exclusion Criteria: - Individuals for whom tight control (ie A1C < 8) is not safe or recommended, including but not limited to older frail individuals at high-risk of hypoglycemia and falls or those with a life expectancy of less than 6 months due to a comorbid condition - Individuals with cognitive or psychological diagnoses that might make CGM or low carbohydrate dieting risky, such as patients with eating disorders, uncontrolled psychotic - mental illness or those patients with dementia - Women who are pregnant or breast feeding - Individuals who had previous bariatric surgery

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Usual Care
Usual care from Primary Care Physician and dietitian.
Behavioral:
Intensive Behavioral Intervention
The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
Other:
Monthly Screening for Risk
Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.

Locations

Country Name City State
United States Chelsea Health Center Chelsea Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan Twine Clinical Consulting

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hemoglobin A1C Hemoglobin A1C 1 year
Secondary Weight Change Difference in patient's weight measured in pounds. baseline to 1 year
Secondary Change in diabetes medication requirements Change in average daily doses of diabetes medications baseline to 1 year
Secondary Change in percentage of time glucose is out of range Change in percentage of time glucose is out of range (70 mg/dl-140 mg/dl) on CGM. baseline to 1 year
Secondary Blood Pressure Blood Pressure 1 year
Secondary Change in rate of Micro-vascular complications Change in rate of micro-vascular complications. (The micro-vascular complications assessed will be retinopathy, neuropathy, nephropathy) Baseline to 1 Year
Secondary Change in rate of symptomatic hypoglycemia requiring medical intervention Change in rate of symptomatic hypoglycemia requiring medical intervention Baseline to 1 year
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance